Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts

Impact · against what's priced in

Celldex gains a positive catalyst from accelerated Phase 3 enrollment for barzolvolimab, shortening the window to pivotal data. The diversification into CDX-622 further mitigates the binary risk associated with its lead CSU asset.

CLDX+0.60

No priced-in read yet

In context

Completing EMBARQ-CSU 1 and 2 enrollment six months ahead of schedule accelerates the path to pivotal data in Sept/Oct 2026 and a 2027 BLA filing. Early safety data for CDX-622 provides a secondary growth vector beyond CSU.

Read from the article alone

• biotech
• pharmaceuticals
• CLDX
• asthma
• clinical trials
• fda approval
• inflammatory disorders
• phase 3

Search tags